Apolipoproteins as markers and managers of coronary risk

QJM: An International Journal of Medicine

Volumn 99, Issue 5, 2006, Pages 277-287

  Chan, D C ^a   Watts, G F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; AUTOMATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DRUG TARGETING; DYSLIPIDEMIA; ECONOMIC EVALUATION; HUMAN; LIPID ANALYSIS; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RELIABILITY; REVIEW; RISK ASSESSMENT; STANDARDIZATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33646254885     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl027     Document Type: Review

References (44)

1. Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8:1211-17.
2. Krauss RM, Kesaniemi YA. Cardiovascular disease and hyperlipidaemia. Curr Opin Lipidol 1994; 5:249-51.
3. Grundy SM. Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy. Circulation 2002; 106:2526-9.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003; 171:145-55.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-39.
6. Adult Treatment Panel III, Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285:2486-97.
7. Packard CJ. Apolipoproteins: The new prognostic indicator? Eur Heart J 2003; 5(Suppl):9-16.
8. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361:777-80.
9. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255:188-205.
10. Chan DC, Barrett PHR, Watts GF. Lipoprotein transport in the metabolic syndrome: Methodological aspects of stable isotope kinetic studies. Clin Sci 2004; 107:221-32.
11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-28.
12. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation 1996; 94:273-8.
13. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25:553-9.
14. Walldius, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358:2026-33.
15. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apoB and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22:1918-23.
16. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: Results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26:271-8.
17. Jiang R, Schulze MB, Li T, et al. Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes. Diabetes Care 2004; 27:1991-7.
18. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. JAMA 2005; 294:326-33.
19. Shai I, Rimm EB, Hankinson SE, et al. Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines. Circulation 2004; 110:2824-30.
20. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99:2517-22.
21. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364:937-52.
22. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation 2000; 101:477-84.
23. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in the Ischemic Disease (LIPID) Trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105:1162-9.
24. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453-60.
25. Roeters van Lennep JE, Westerveld HT, van Roeters Lennep HWO, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000; 20:2408-13.
26. Friedewald WT. Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
27. Snidermann AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002; 90(suppl):48-54i.
28. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001; 39:426-31.
29. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39:773-81.
30. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care 2003; 26:16-23.
31. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161:1413-19.
32. Schulze MB, Shai I, Manson JE, Li T, Rifai N, Jiang R, Hu FB. Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. Diabetologia 2004; 47:2129-36.
33. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91:1173-7.
34. Kim BJ, Kwang ST, Sung KC, et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005; 51:2257-63.
35. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005; 179:339-44.
36. Haffner SM. American Diabetes Association., Management of dyslipidaemia in adults with diabetes. Diabetes Care 2003; 26:S83-6.
37. Ballantyne CM, Arroll B, Shepherd J. Lipids and CVD management: Towards a global consensus. Eur Heart J 2005; 26:2224-31.
38. Collins-Nakai RLC, Dagenais GR. The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary. Can J Cardiol 1999; 15:7-10G.
39. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Lipid management guidelines - 2005. Heart Lung Circ 2005; 14:275-91.
40. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoproteinB: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001; 88:265-9.
41. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
42. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial, Lancet 2002; 360:7-22.
43. LaRosa JC, Grundy SM, Waters DD, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005; 352:1425-35.
44. Sniderman AD, Cabezas MC, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia - third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32:71-3.